Celltrion USA launches ZYMFENTRA for ulcerative colitis and Crohn’s disease

Celltrion USA launches ZYMFENTRA for ulcerative colitis and Crohn’s disease

In a significant advancement for patients with digestive disorders, Celltrion USA has announced the availability of ZYMFENTRA (infliximab-dyyb), marking it as the first and only subcutaneous formulation of infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023. This revolutionary treatment offers a new hope and convenience for adults suffering from moderately to […]